American Diabetes Association
Browse
Supplementary_KleinLingvay_MetforminGLP1RA_GIAdverseEvents_26Oct2023.pdf (201.48 kB)

Occurrence of Gastrointestinal Adverse Events upon GLP-1 Receptor Agonist Initiation with Concomitant Metformin Use: a post-hoc analysis of LEADER, STEP-2, SUSTAIN-6, and PIONEER-6

Download (201.48 kB)
figure
posted on 2023-12-04, 21:18 authored by Klara R. Klein, Kim K. B. Clemmensen, Edwin Fong, Søren Olsen, Trine Abrahamsen, Ildiko Lingvay

OBJECTIVE

To assess the impact of concomitant metformin use on gastrointestinal adverse events during the initiation and titration of GLP-1RA.

RESEARCH DESIGN AND METHODS

Using data from four clinical trials of liraglutide and semaglutide (LEADER, STEP-2, SUSTAIN-6, and PIONEER-6), we compared the incidence of gastrointestinal adverse events during GLP-1RA initiation and titration in participants with and without concomitant metformin use.

RESULTS

Of 16,996 participants, 12,928 (76%) were treated with metformin. Concomitant metformin use did not increase the percentage of participants who developed gastrointestinal adverse events or their severity during the observation window. Among participants experiencing gastrointestinal adverse events, metformin use did not increase study product discontinuation. Within treatment arms (GLP-1RA and placebo), a numerically higher percentage of metformin non-users experienced GI adverse events and discontinued study product compared to metformin users.

CONCLUSIONS

Concomitant metformin use does not increase occurrence of gastrointestinal symptoms during GLP-1RA initiation or impact GLP-1RA discontinuation.

Funding

KRK is supported by the University of North Carolina Department of Medicine and School of Medicine Physician Scientist Training Program.

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC